Literature DB >> 20851293

Is carnosinase 1 gene (CNDP1) polymorphism associated with chronic kidney disease progression in children and young adults? results of a family-based study.

Katarzyna Kiliś-Pstrusińska1, Danuta Zwolińska, Władysław Grzeszczak.   

Abstract

BACKGROUND AND AIMS: The aim of the study was to investigate the role of the D18S880 microsatellite polymorphism of carnosinase 1 gene (CNDP1), which encodes serum carnosinase, in the development and progression of chronic kidney disease (CKD) of nondiabetic etiology.
METHODS: We applied two different approaches. First, a family-based study was carried out comprising 109 patients with CKD caused by chronic glomerulonephritis (GN) or tubulointerstitial nephritis (IN) and their 218 healthy parents using the transmission/disequilibrium test. CNDP1 polymorphism and serum carnosinase activity were determined in all subjects. Serum carnosinase activity was also measured in 20 healthy controls. Second, we performed a case-control study to determine whether polymorphism in CNDP1 gene and other factors influence the progression of renal impairment.
RESULTS: Preferential transmission of the 5 allele of CNDP1 polymorphism from heterozygous parents to their offspring with CKD caused by GN was found. There was no association between that polymorphism and the loss of glomerular filtration rate. Serum carnosinase activity was significantly higher in CKD patients than in controls.
CONCLUSION: This study found no association between the CNDP1 polymorphism and increased risk for development of CKD caused by IN. However, the polymorphism can influence CKD caused by GN. The progression rate of CKD does not depend on this polymorphism. The increased serum carnosinase activity in the CKD patients may suggest its role in the pathomechanism of the disease.
Copyright © 2010 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851293     DOI: 10.1016/j.arcmed.2010.07.006

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

1.  Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes.

Authors:  T S Ahluwalia; E Lindholm; L C Groop
Journal:  Diabetologia       Date:  2011-05-15       Impact factor: 10.122

Review 2.  Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.

Authors:  Verena Peters; Johannes Zschocke; Claus P Schmitt
Journal:  J Inherit Metab Dis       Date:  2017-10-13       Impact factor: 4.982

3.  The CNDP1 (CTG)5 Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration.

Authors:  Thomas Albrecht; Shiqi Zhang; Jana D Braun; Li Xia; Angelica Rodriquez; Jiedong Qiu; Verena Peters; Claus P Schmitt; Jacob van den Born; Stephan J L Bakker; Alexander Lammert; Hannes Köppel; Peter Schnuelle; Bernhard K Krämer; Benito A Yard; Sibylle J Hauske
Journal:  J Diabetes Res       Date:  2017-05-03       Impact factor: 4.011

4.  Monoclonal Antibody RYSK173 Recognizes the Dinuclear Zn Center of Serum Carnosinase 1 (CN-1): Possible Consequences of Zn Binding for CN-1 Recognition by RYSK173.

Authors:  Shiqi Zhang; Holger A Lindner; Sarah Kabtni; Jaap van den Born; Stephan Bakker; Gerjan Navis; Bernard Krämer; Benito Yard; Sibylle Hauske
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

5.  Serum Carnosinase-1 and Albuminuria Rather than the CNDP1 Genotype Correlate with Urinary Carnosinase-1 in Diabetic and Nondiabetic Patients with Chronic Kidney Disease.

Authors:  Angelica Rodriguez-Niño; Sibylle J Hauske; Anna Herold; Jiedong Qiu; Jacob van den Born; Stephan J L Bakker; Bernhard K Krämer; Benito A Yard
Journal:  J Diabetes Res       Date:  2019-12-24       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.